TPharm5 Draft RFP READ FIRST 20191202.docx

TRICARE Pharmacy Services, 5th Generation (TPharm5) DRAFT Request for Proposals (RFP)

HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime. The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by: Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation. DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years. The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments. This posting is intended solely for information and planning purposes only, and is NOT a solicitation. Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached. Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments. DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program. DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

1. §C.1.1.1 Use of Statements of Objectives

1. §C.3.3 Specialty

1. §C.3.4.2 Retail Network Access

1. §C.6.3.5 Compounded Medications

1. §C.6.3.6 Care Coordination

1. §C.7.11.2 Patient Safety Notification

1. §C.13.1.1 Quality Control DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement. Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government. If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado. DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website. Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities. It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil. Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/ Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445# Participation in groups is encouraged to reduce the number of individual sessions created.